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CORONARY-Chronic Total Occlusion
CRT-138
Native Coronary Artery Patency Following Coronary Artery Bypass Surgery
David Pereg, Bradley Strauss
Sunnybrook Hospital, Toronto, ON, Canada
Background: In contrast to the large body of information regarding graft patency,
data regarding atherosclerosis progression and vessel patency in surgically bypassed
native coronary arteries are less clear. We aimed to determine native coronary artery
patency one year after CABG, and to identify clinical and angiographic predictors for
developing a chronic total occlusion (CTO).
Methods: Included in our study were 388 patients who underwent 1-year follow-up
angiography as part of the multi-centre Radial Artery Patency Study (RAPS). An-
giograms were reviewed for native coronary artery patency in an independent blinded
manner.
Results: In the pre-operative angiogram, CTO of at least one native coronary vessel
was demonstrated in 240 (61.9%) patients having 305 occluded vessels. At 1 year post
CABG, at least 1 new native coronary artery CTO occurred in 169 (43.6%) patients.
In 7.5% of patients, the native artery and the graft supplying that territory were both
occluded. A new CTO was almost ﬁve times more likely to occur in coronary vessels
with a pre-operative proximal stenosis >90% compared to vessels with proximal
stenosis <90% (45.5% versus 9.5% respectively, p<0.001). Patients with a new CTO
had signiﬁcantly more baseline CCS class 4 angina, and higher creatinine levels
compared to patients without a new CTO. A new CTO was less likely to occur in the
LAD (18.4%), supplied by the LITA. When comparing radial artery and SVGs,
neither the type of graft nor graft patency had any association with native coronary
artery occlusion.
Conclusions: CTO of surgically bypassed coronary arteries 1 year following CABG is
extremely common, suggesting accelerated progression of atherosclerosis in these
vessels.
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Background: Bare metal stents (BMS) have similar rates of death and myocardial
infarction (MI) to drug-eluting stents (DES). DES lower rates of repeat revasculari-
zation compared to BMS, but may have higher rates of late and very late stent
thrombosis (ST). This is potentially due to impaired endothelialization which requires
longer dual anti-platelet therapy (DAPT) compared with BMS.Methods: The OMEGA study is a prospective, multicenter, single-arm study
enrolling 328 patients at 37 investigative sites in the US and EU. Patients received the
OMEGA stent (also known as REBEL; a bare platinum chromium Element stent)
for the treatment of de novo native coronary artery lesions (28 mm long;
diameter 2.25 mm to 4.50 mm). The primary endpoint was 9-month target lesion
failure (TLF: cardiac death, target vessel-related MI, target lesion revascularization
[TLR]) compared to a prespeciﬁed performance goal (PG) based on prior generation
BMS. All major cardiac events were independently adjudicated. DAPT was required
for a minimum of 1 month post procedure.
Results: In the OMEGA study, the mean age was 65; 17% had diabetes mellitus.
Approximately 29% had previous PCI, 5% had previous CABG (Table). The primary
endpoint was met; the 9 month TLF rate was 11.5% and the upper 1-sided 95%
conﬁdence bound of 14.84% was less than the prespeciﬁed PG of 21.2% (p<0.0001).
Event rates were low including a ST rate of 0.6% at 9 months (Table). Through
9 months, the MI rate was 3.7% (12/326); all of the MIs were non-Q wave MIs most
occurring within 1 day of the procedure (10/12).
Conclusion: Nine-month outcomes of OMEGA show a low rate of TLF, revascu-
larization and ST events. This supports safety and efﬁcacy of the novel, platinum
chromium OMEGA/REBEL BMS for the treatment of coronary artery disease.Baseline Clinical CharacteristicsMale, % 67.7% (222/328) Stable Angina, % 49.7% (163/328)Age, years 65.4611.23 (328) Unstable Angina, % 31.1% (102/328)
Diabetes*, % 17.4% (57/328) Hyperlipidemia*, % 70.8% (230/324)Smoking
(ever), %66.1% (211/319) Hypertension*, % 75.0% (243/324)History of
Bleeding
Disorder, %2.5% (8/326) Prior MI, % 29.0% (94/324)History of TIA
or CVA, %7.7% (25/326) Prior PCI, % 28.8% (94/326)History of
PVD, %6.4% (21/326) Prior CABG, % 4.6% (15/327)Baseline Lesion CharacteristicsRVD, mm 2.770.53 (327) % DS 67.4111.34 (327)
MLD, mm 0.900.38 (327) Lesion Length (mm) 12.495.15 (327)
9-Month Outcomes (Intent-to-treat)TLF 11.4% (37/324) TVR 8.6% (28/326)Cardiac Death 1.2% (4/326) TLR 7.4% (24/326)MI** 3.7% (12/326) Stent Thrombosis
(ARC ST;
Deﬁnite/Probable)0.6% (2/320)TIA: Transient Ischemic Attack; CVA: Cerebrovascular Accident; PVD: peripheral vascular disease;
RVD: Reference Vessel Diameter; MLD: Minimum Lumen Diameter; %DS: Percent Diameter
Stenosis; PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft surgery;
TLF: cardiac death, myocardial infarction (MI) related to the target vessel, and target lesion
revascularization (TLR); *Requiring medication; **All were non-Q-Wave MI deﬁned as elevation
of post-procedure CK-MB levels to >3.0 times ULN without new Q-waves.
